ROCKET-AF Heart Failure Subgroup Risk Index

Clinical calculation support · Verify results before clinical use

Important clinical limitation: The point weights and score are illustrative only. No validated conversion from this score to annual stroke/systemic embolism risk is available. Do not use this index to estimate an individual patient's risk or guide anticoagulation decisions.

Patient characteristics

Complete all categorical fields. Creatinine may be left blank if unavailable.

— Points
Age ≥75 years contributes 1 experimental point.
The proposed criterion is EF <40% or NYHA class III–IV.
Optional. The proposed criterion is ≥1.5 mg/dL (+1 point). Leave blank if unavailable; a blank value does not add a point.
Reset form

About this experimental index

ROCKET-AF was a randomized trial comparing rivaroxaban with warfarin in patients with nonvalvular atrial fibrillation at increased risk of stroke. A subsequent analysis examined efficacy and safety outcomes among participants with heart failure.

This page implements a proposed educational composite using selected patient characteristics. The assigned weights were not derived from a published, validated ROCKET-AF heart-failure point score, and the total has not been shown to predict a specific probability of stroke, systemic embolism, bleeding, or death.

Proposed point allocation

CriterionDefinition in this toolPoints
Age≥75 years+1
Prior stroke/TIAHistory present+2
HF severityEF <40% or NYHA III–IV+1
Creatinine≥1.5 mg/dL+1
DiabetesHistory present+1
HypertensionHistory present+1
Vascular diseasePrior MI or PAD+1
AF typePersistent or permanent+1

Clinical interpretation

Do not interpret the numerical total as a validated risk estimate. For stroke prevention decisions in atrial fibrillation, use a guideline-recommended, validated risk assessment approach and individual clinical evaluation. This tool does not assess bleeding risk or determine anticoagulant choice or dose.

References

Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation.

New England Journal of Medicine. 2011;365:883–891.

DOI: 10.1056/NEJMoa1009638 · PubMed: 21830957

van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.

Circulation: Heart Failure. 2013;6(4):740–747.

DOI: 10.1161/CIRCHEARTFAILURE.113.000212 · PubMed: 23723250

Clinical disclaimer: This is an experimental, non-validated educational composite. Its point weights are not a published prediction rule, and it has no validated risk calibration. It must not be used as the sole basis for clinical decisions, anticoagulation, or patient counselling about absolute event probabilities.